242
Participants
Start Date
April 25, 2022
Primary Completion Date
February 17, 2025
Study Completion Date
February 28, 2027
Mosunetuzumab
Participants will receive SC mosunetuzumab on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-8 (cycle length = 21 days).
Polatuzumab vedotin
Participants will receive IV polatuzumab vedotin every three weeks (Q3W) for 6 cycles (cycle length = 21 days).
Tocilizumab
Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events.
Rituximab
Participants will receive IV rituximab on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Gemcitabine
Participants will receive IV gemcitabine on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Oxaliplatin
Participants will receive IV oxaliplatin on Day 1 of each cycle for 8 cycles (cycle length = 14 days).
Oncosalud Sac, Lima
Hospital Aleman, Buenos Aires
Instituto Alexander Fleming, Buenos Aires
Instituto Regional de Enfermedades Neoplásicas del Sur, Arequipa
Chulalongkorn University Hospital, Bangkok
Siriraj Hospital, Bangkok
Superare Centro de Infusion S.A. de C.V., Mexico City
Instituto Nacional de Cancerologia, Distrito Federal
Medipol Mega Üniversite Hastanesi Göztepe, Istanbul
Chungnam National University Hospital, Daejeon
Dokuz Eylul Universitesi Tip Fakultesi, Lzmir
Srinagarind Hospital, Khon Kaen Uni, Khon Kaen
Anadolu Health Center, Kocaeli
Pusan National University Hospital, Busan
Chiang Mai Uni Hospital, Chiang Mai
St. Luke's Hospital, Chesterfield
Hospital Universitario Dr. Jose E. Gonzalez, Monterrey
MD Anderson Cancer Center, Houston
Ascension Seton Infusion Center, Austin
City of Hope Cancer Center, Duarte
Tianjin Cancer Hospital, Tianjin
Fujian Medical University Union Hospital, Fuzhou
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech, Wuhan
Henan Cancer Hospital, Zhengzhou
Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou
Sichuan Cancer Hospital, Chengdu
Ichilov Sourasky Medical Center, Tel Aviv
Soroka Medical Center, Beersheba
FUNDALEU, Buenos Aires
Hospital Italiano de Buenos Aires, Ciudad Autonoma Buenos Aires
Hospital Erasto Gaertner, Curitiba
Hospital das Clinicas - UFRGS, Porto Alegre
Hospital das Clínicas FMRP-USP, Ribeirão Preto
Hospital Sao Jose, São Paulo
D'or Instituto de Pesquisa e Educação, São Paulo
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, México
Middlemore Clinical Trials, Auckland
Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton
Princess Margaret Hospital, Toronto
Chum Hopital Notre Dame, Montreal
Kyushu University Hospital, Fukuoka
Hokkaido University Hospital, Hokkaido
Tohoku University Hospital, Miyagi
Kindai University Hospital, Osaka
The Cancer Institute Hospital of JFCR, Tokyo
Yamagata University Hospital, Yamagata
Health Pharma Professional Research, Mexico City
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
Yeouido St. Mary's Hospital, Seoul
Ankara University Medical Faculty, Ankara
Hoffmann-La Roche
INDUSTRY